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Abstract.  T  cell adhesion to endothelium is critical to 
lymphocyte recirculation and influx into sites of 
inflammation.  We have systematically analyzed the 
role of four receptor/ligand interactions that mediate 
adhesion of peripheral human CD4+  T cells to cul- 
tured human umbilical vein endothelial ceils 
(HUVEC): T cell LFA-1 binding to ICAM-1  and an al- 
ternative ligand ("ICAM-X'), T  cell VLA-4 binding to 
VCAM-1,  and T cell binding to ELAM-1.  Contribu- 
tions of these four pathways depend on the activation 
state of both the T  cell and HUVEC, and the differen- 
tiation state of the T cell.  ELAM-1 plays a  significant 
role in mediating adhesion of resting CD4+  T  cells to 
activated HUVEC. LFA-1 adhesion dominates with 
PMA-activated T  cells but the strength and the pre- 
dominant LFA-1 ligand is determined by the activation 
state of the HUVEC; while ICAM-1 is the dominant 
ligand on IL-l-induced HUVEC, "ICAM-X" dominates 
binding to uninduced HUVEC. Adhesion via VLA-4 
depends on induction of its ligand VCAM-1  on acti- 
vated HUVEC; PMA activation of T  cells augments 
VLA-4-mediated adhesion, both in the model of 
T/HUVEC binding and in a simplified model of T cell 
adhesion to VCAM-l-transfected L cells.  Unlike LFA-1 
and VLA-4, ELAM-l-mediated adhesion is not in- 
creased by T cell activation.  Differential expression of 
adhesion molecules on CD4+  T  cell subsets under- 
stood to be naive and memory cells also regulates 
T/HUVEC adhesion.  Naive T  cell adhesion to 
HUVEC is mediated predominantly by LFA-1 with lit- 
tle or no involvement of the VLA-4 and ELAM-1 
pathways. In contrast, memory T  cells bind better to 
HUVEC and utilize all four pathways. These studies 
demonstrate that there are at least four molecular 
pathways mediating T/HUVEC adhesion and that the 
dominance/hierarchy  of these pathways varies dramati- 
cally with the activation state of the interacting  cells 
and the differentiation state of the T  cell. 
I 
N the immune system, the process of adhesion is critical 
to two distinct  but related processes to T lymphocyte 
function:  T cell recognition  of foreign antigen,  and the 
nonrandom migration  or trafficking  of lymphocytes to dis- 
tinct anatomic sites in vivo (27, 41, 49, 51). The attachment 
of T lymphocytes to endothelial  cells and subsequent migra- 
tion between endothelial  cells into the surrounding  tissue is 
critically  important  to  lymphocyte  migration.  Evidence 
from a number of studies suggest that at least four molecular 
pathways of adhesion mediate T cell binding to cultured hu- 
man umbilical vein endothelial  cells (HUVEC)  1 (illustrated 
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schematically  in Fig.  1).  The LFA-1 integrin  (also CDlla/ 
CD18) has been shown to mediate  lymphocyte binding  to 
HUVEC  by  binding  its  well-known  ligand  ICAM-1 (10, 
26,  28)  and  an undefined  ligand,  designated  in this paper 
"ICAM-X" (10). An additional  LFA-1 ligand,  ICAM-2, has 
been cloned from HUVEC (50),  but the functional  role of 
ICAM-2 in T/HUVEC adhesion awaits further analysis. Var- 
ious studies suggesting that T/HUVEC adhesion can also be 
mediated by an LFA-l-independent  mechanism  (1,  10,  39) 
have  been  confirmed  by the  identification  of two LFA-1- 
independent pathways of T/HUVEC adhesion.  One pathway 
is mediated by the inducible endothelial  cell adhesion mole- 
cule VCAM-1 (6, 33, 36, 39); the lymphocyte molecule that 
binds VCAM-1 has recently been identified  as the VLA-4 
(also a4/~1) integrin  (6, 12, 39), which also mediates  adhe- 
sion to fibronectin  (13, 16, 45, 56). We have recently char- 
acterized  a novel pathway of T/HUVEC adhesion  involving 
the inducible  endothelial  cell surface protein ELAM-1  (15, 
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Figure 1. Four molecular path- 
ways of adhesion involved in 
T  cell  binding to  cultured 
HUVEC. T cell adhesion to 
activated HUVEC expressing 
multiple  adhesion  molecules 
is illustrated (see text for de- 
tails). An undefined ELAM-1 
ligand on T  cells is identified 
by  ???. 
43), which also mediates granulocyte adhesion to activated 
HUVEC (3, 32).  Thus, at least four adhesion pathways ap- 
pear to mediate T/HUVEC adhesion: LFA-1/ICAM-1, LFA- 
1/"ICAM-X" VLA-4/VCAM-1,  and ELAM-1. 
Several independent lines of evidence suggest that T cell 
adhesion to endothelial cells can be regulated in multiple 
ways.  First, activation of HUVEC  by inflammatory cyto- 
kines such as IL-1/3 and TNF-t~ results in a rapid increase 
in expression of ICAM-1  and induced expression of both 
VCAM-1 and ELAM-1 on the endothelial cell surface (2, 10, 
33, 35).  The increased expression of these adhesion mole- 
cules  on activated endothelium is thought to represent  a 
mechanism by which various leukocyte populations can be 
rapidly recruited into a site of inflammation or tissue injury 
(20,  32, 51, 53, 57). 
Second, the activation state of the T cell is particularly 
critical in regulating the function of integrins such as LFA-1 
and VLA-4 (44, 49). Dustin and Springer first demonstrated 
that while LFA-l-mediated adhesion of resting T  cells to 
ICAM-1 is minimal, activation of the T cell with the phorbol 
ester PMA or cross-linking of the T  cell receptor results 
within minutes in strong LFA-l-mediated adhesion without 
a change in levels of cell surface LFA-1 (11). Similar results 
have been shown for the VLA-4, VLA-5, and VLA-6 inte- 
grins (44,  45),  suggesting a  common mode of activation- 
dependent regulation of integrins on human T cells. 
Third, an additional mode of regulation of T cell adhesion 
is related to changes in the level of adhesion molecule ex- 
pression as a consequence of T cell differentiation. A num- 
ber of adhesion molecules, including LFA-1 and VLA-4, are 
differentially expressed on reciprocal subsets of CD4+  T 
cells defined as "naive" and "memory"  cells (37, 38, 44, 45). 
The greater expression of adhesion molecules on memory T 
cells is associated with greater memory cell adhesion to 
purified ligands such as ICAM-1, fibronectin, and laminin, 
and to other cells (7, 9,  34, 44, 45). 
The aim of this study was to integrate these independent 
findings and systematically analyze how these three modes 
of regulation interact and affect the adhesion of human pe- 
ripheral CD4 +  T cells to HUVEC. The results show that the 
ensemble of molecular pathways used in any situation is de- 
termined by the combination of these three parameters. Fur- 
thermore, we demonstrate an important role for ELAM-1 in 
adhesion of resting T cells to activated HUVEC and demon- 
strate for the first time activation-dependent regulation of 
VLA-4 adhesion to VCAM-1. 
Materials and Methods 
Cells and Culture Reagents 
HUVEC were isolated and cultured as previously described (15) in M199 
media containing 20% FCS (Hyclone Laboratories, Logan, UT), 90 t~g/rnl 
preservative-free  porcine heparin, 20 t~g/ml endothelial cell growth supple- 
ment, and antibiotics.  All HUVEC were used fresh at passage 2 or less. 
Mouse  L  ceils were  cultured  by standard procedures in IMEM media 
(Biofluids, Inc., RockviUe, MD) containing 5%FCS and antibiotics.  Rest- 
ing human peripheral CIM+ T cells are isolated from normal donors by 
rigorous  negative immunoselection with magnetic beads as previously  de- 
scribed (18). Negative  selection is performed with a  cocktail of mAbs 
against HLA class H on B cells, activated T cells, and monocytes (IVA12), 
CD20 on B cells (1F5), CD16 on NK cells (3G8), CDllb on monocytes 
(NIHllb-1),  CD14  on monocytes (MMA),  glycophorin on erythrocytes 
(10F7), and CD8 (B9.8); purity of the CD4+ T cells was >98%. Presence 
of the HLA class II mAb IVA12 excluded the normal low percentage of acti- 
vated T  cells  from  the  final  isolated cell  population.  Purified  CD4+ 
CD45RA+ naive and CD4+CD45R0+  memory T cells were isolated by 
the same procedure with the same mAb cocktail except the CD45R0 mAb 
UCHL1 was added to negatively select memory T ceils and the CD45RA 
mAb Gl-15 was added to negatively  select naive T cells. 
mAbs 
All of the following mAbs were used as dilutions of ascites fuld: CD20 
mAb 1F5 and CD45RA mAb GI-15 (24), CDI6 mAb 3G8 (D. Segal, Na- 
tional Institutes of Health, Bethesda, MD), CD14 mAb MMA and glyco- 
phorin mAb 10F7 (American Type Culture Collection, RockviUe, MD), 
CD8 mAb B9.8 (B. Malissen, Centre d'Immunologie,  Marseilles),  and the 
CIMSR0  mAb UCHL1  (48).  All of the following  mAbs were used as 
purified IgG:  HLA class II mAb IVA12 (ATCC),  CDllb mAb NIHllb-1 
(19), LFA-1 ~ chain mAb MHM24 (17), LFA-1/3 chain rnAb MHM23 (17), 
VCAM-1 mAb 2G'/(15), ELAM-1  mAb 7A9 (15), CIM5 mAb NIH45-2 
(43), ICAM-1 mAbs W-CAM-1 (4) and 84H10 (26),  VLA-4 c~ chain mAb 
L25 (8, 52), VLA/3 chain mAb MAB 13 (30), and the VLA-5 c¢ chain mAb 
MAB 16 (30). 
Flow Microfluorometry 
Flow microfluorometry of  resting and IL-l-activated HUVEC was performed 
as previously  described (15) using a flow cytometer model 541  (Coulter 
Electronic,  Hialeah, FL) equipped  with an argon laser and a quartz flow 
cell. 
Generation  of VCAM-1 L Cell Transfectants 
Mouse L cell transfectant clone LVE3 was isolated by cotransfection of L 
cells with separate plasmids containing VCAM-I and ELAM-1 cDNAs, and 
pRSVNeo by the CaPO4 coprecipitation method. Stable transfectant clones 
were isolated by selection with G418 antibiotic,  and tested for membrane 
expression of VCAM-1 and ELAM-1 by antibody binding with the 2G7 and 
7A9 antibodies, respectively (15). One clone, LVE3, showed binding of anti- 
VCAM-1 (2G7) mAb but not of anti-ELAM-1  (7A9) mAb. This clone also 
did not produce detectable levels of ELAM-1 mRNA by Northern analysis 
(not shown). 
Cell Adhesion Assays 
Binding of CIM+ T cells to HUVEC was assessed as previously described 
(15, 43). Briefly, HUVEC were plated onto gelatin precoated 24-well plates 
(Costar Corp., Cambridge, MA) and cultured for 48 hours or until con- 
fluent; L cells were plated onto uncoated 24-well plates and cultured to con- 
fluence.  HUVEC were activated by exposure to 1 ng/ml IL-I~ in medium 
(RPMI/IO% FCS) for 4 h at 37°C and then washed once with medium im- 
mediately before addition ofT cells. CIM+ T cells were labeled with Cr-51 
and 300,000  T cells were added to each well in a final volume of 300 t~l. 
For assessing adhesion of acutely activated T cells, CIM+ T cells were pre- 
activated by incubation for 20 rain with 10 ng/ml PMA (Sigma Chemical 
Co., St. Louis, MO) before washing and addition to the HUVEC monolayer. 
Where blocking by mAbs was assessed, binding was assessed in the contin- 
uous presence of antibody; all mAbs were used at a saturating concentration 
of 10 t~g/ml, which has been shown in previous studies to maximally inhibit 
the relevant adhesive interaction (15, 44--46, 55). Plates were incubated for 
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activation state of  both cell types. Adhesion of  Cr-5 I-labeled resting 
(solid bars) or PMA-activated (shaded  bars) CD4+ T cells to rest- 
ing HUVEC or HUVEC preexposed for4 h to IL-I~ (IL-1 induced) 
was assessed as described in Materials and Methods. Results from 
two independent experiments using CD4+  T ceils from different 
donors is presented. Data are expressed as mean percent of cells 
binding from duplicate wells. 
30 minutes at 37°C, and then gently washed twice with RPMI/10%  FCS 
media at room temperature to remove nonadherent T cells. Contents of each 
well containing adherent T cells were lysed with 300 #1 of 1% Triton X-100 
and "y-emissions  were counted. Data are expressed as mean percent of ceils 
binding. No differences in overall adhesion, utilization of  adhesion pathways 
under different activation conditions, or phenotype of adhesion molecules 
was observed between freshly isolated CD4+  T ceils and purified CD4+ 
T  cells that were cryopreserved in liquid nitrogen and thawed before use. 
All experiments were performed a minimum of three times using different 
donor T  cells and HUVEC; data presented represent results from one or 
two representative experiments. 
Results 
T CellAdhesion to Endothelium Is Dependent on 
the Activation State of Both Cell 7)~pes 
Binding of resting peripheral blood CD4+  T cells to early 
passage cultured HUVEC was assessed using an in vitro ad- 
hesion assay (15).  Fig. 2 shows  that there is minimal adhe- 
sion of resting CD4+ T ceils to resting HUVEC. However, 
pretreatment of HUVEC for 4 h with IL-I~ results in the in- 
duced expression of the adhesion molecules VCAM-1  and 
ELAM-1 and increased expression of  ICAM-1 (Fig. 3). These 
phenotypic changes in adhesion molecule expression on acti- 
vated HUVEC are associated with increased binding of rest- 
ing CD4+ T cells (Fig. 2). While activation of HUVEC re- 
sults  in  increased  T  cell binding,  acute activation of the 
CD4+  T cells results in even greater T/HUVEC adhesion. 
Preactivation of CD4+ T cells for 20 rain with the phorbol 
ester PMA results in increased adhesion to both resting and 
IL-l-induced HUVEC compared to resting CIM+  T  cells 
(Fig. 2). Thus, T cell adhesion to HUVEC is dynamically 
regulated by the activation state of  both interacting cell types. 
The LFA-1 and VCAM-1 Pathways Mediate Adhesion 
of PMA-activated T Cells to HUVEC 
mAb blocking studies were used to define the contribution 
of the LFA-1, VCAM-1, and ELAM-1 adhesion pathways to 
the binding of PMA-activated CD4+  T  cells to HUVEC. 
Adhesion of PMA-activated T cells to resting HUVEC is in- 
m 
z 
,.-.1 
r..b 
0  50  1C~  150  200  250 
'ii  ,  ,  ,c  ' 
50  L..: 
zs  :-';  ' 
o 
0  50  I00  150  200  250 
'°°l  '1 
75 "  50  ;' 
25 
o 
0  50  ~  oo  150  2o0  250 
lOO 
50 
25 
0  50  100  150  200  250 
CHANNEL  NUMBER 
Figure 3.  Activation of HUVEC  with IL-1/3 results in increased 
ICAM-I  expression  and  induced  expression  of  VCAM-1 and 
ELAM-1. Expression of VCAM-1 (B), ELAM-1 (C), and ICAM-1 
(D) on resting (dotted  lines) and IL-l-induced (solid lines) HUVEC 
was  assessed by flow cytometry  as described  in Materials  and 
Methods. Background binding in the presence of the second step 
goat anti-mouse Ig FITC reagent only is shown in A. mAbs used 
were 2G7 (VCAM-l-specific), 7A9 (ELAM-l-specific), and 84H10 
(  ICAM-l-specific). 
hibited by an LFA-1 mAb alone while neither a VCAM-I-spe- 
cific or an ELAM-l-specific mAb alone has any inhibitory 
effect (Fig.  4,  C-E).  The lack of effect of VCAM-1  and 
ELAM-1 mAbs on binding to resting HUVEC is not surpris- 
ing, since resting HUVEC do not express either VCAM-1 or 
ELAM-1 (Fig. 3). Pairwise combinations of LFA-1, VCAM-1, 
and ELAM-1 mAbs along with all three mAbs together fail 
to show greater inhibition than seen with the LFA-1 mAb 
alone (C vs. F-l, Fig. 4), suggesting that the LFA-1 pathway 
predominates  in  mediating  adhesion  of PMA-activated  T 
cells to resting HUVEC. 
Activation of HUVEC with IL-1 results in the induction of 
VCAM-1 and ELAM-1 expression (Fig. 3). Compared with 
the inhibition of PMA-activated T  cell adhesion to resting 
HUVEC,  the LFA-1 mAb  is  not as  effective in  inhibiting 
adhesion to IL-l-induced HUVEC (Fig.  4  C);  neither the 
VCAM-1 or ELAM-1 mAbs alone show any significant inhibi- 
tion of binding. However, combinations of LFA-1, VCAM-1, 
and ELAM-1  mAbs clearly demonstrate a  contribution of 
VCAM-1 and, to a lesser extent, ELAM-1. A role for VCAM-1 
is shown by the fact that inhibition of binding by the combi- 
nation of LFA-1 and VCAM-1  mAbs is greater than either 
mAb alone (compare F and C, Fig. 4). Furthermore, binding 
is maximally inhibited by the combination ofLFA-1, VCAM-1, 
and  ELAM-1  mAbs,  suggesting  some  involvement of the 
ELAM-1 pathway (I, Fig. 4). Although some adhesion is still 
detectable in the presence of LFA-1, VCAM-1 and ELAM-1 
mAbs,  such as in PMA-activated T  cell binding to resting 
HUVEC, we have not been able to further inhibit adhesion 
with the addition of mAbs specific for other adhesion mole- 
cules, such as CD2 and CD44 (data not shown). 
Further studies aimed at defining receptor/ligand relation- 
ships show that a VLA-4 mAb is as effective as a VCAM-1 
mAb in blocking PMA-activated T cell adhesion to IL-l-in- 
duced HUVEC (D vs. Fin Fig. 5), suggesting that additional 
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Figure 4. Binding of PMA-activated CD4+ T cells to HUVEC in- 
volves multiple adhesion pathways mediated by LFA-1, VCAM-1, 
and ELAM-I. Binding of PMA-activated CD4+ T cells to resting 
(left) or IL-l-induced HUVEC (right) was assessed in the presence 
of  the indicated mAbs. Adhesion  was restricted to specific  pathways 
(Fig. 1) by adding mAbs to block the other pathways. Binding was 
assessed in the continuous presence of the indicated mAbs at a 
saturating concentration of 10 #g/ml for each mAb, except for the 
control mAb NIH45-2, which was used at 20 #g/ml. Equivalent 
blocking was seen with the LFA-1 c~ chain mAb MHM24 (as shown 
in the figure) or the LFA-113  chain mAb MHM23 (not shown). Inhi- 
bition seen with pairwise combinations of LFA-I, VCAM-I, and 
ELAM-1 mAbs was unaffected by the addition of a control mAb, 
the VLA-5-specific mAb MAB 16 (30). Furthermore, inhibition 
was not increased by the addition of MAB 16 to the maximally in- 
hibitory combination of LFA-1, VCAM-I,  and ELAM-1 mAbs (data 
not shown). Data are expressed as mean percent of cells binding 
from duplicate wells. 
molecules on the T cell other than VLA-4 are not involved 
in VCAM-l-mediated adhesion.  In contrast, mAbs specific 
for the LFA-1 ligand ICAM-1 are not as effective as an LFA-1 
mAb in blocking binding of PMA-activated T cells to either 
resting  or IL-l-induced HUVEC  (C vs.  D,  Fig.  5).  Even 
though the two ICAM-1 mAbs used potently inhibit LFA-1/ 
ICAM-1 interactions at the concentrations used (4, 42, 55, 
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A  NONE 
B  Anti-VCAM-1 + Anti-ELAM-1 
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Figure 5.  Roles of VLA-4 and ICAM-1 in mediating adhesion of 
PMA-activated CD4+ T cells to HUVEC. Binding of PMA-acti- 
vated CD4+  T  cells to  resting (left) and  IL-l-induced (right) 
HUVEC was assessed in the presence of  the indicated combinations 
of mAbs to restrict binding to a specific adhesion pathway (Fig. 1). 
Binding was assessed in the continuous presence of mAb at a satu- 
rating concentration of I0 #g/ml for each mAb. Comparable block- 
ing  results were obtained  with  two inhibitory  ICAM-1 mAbs, 
W-CAM-1 (shown) and 84H10 (not shown). Data are expressed as 
mean percent of cells binding from duplicate wells. 
Figure 6. Acute  T cell activation increases LFA-1-  and VLA-4- but 
not ELAM-l-dependent adhesion to IL-l-induced HUVEC. Bind- 
ing of resting (solid  bars) or PMA-activated (shaded bars) CD4+ 
T cells to IL-l-induced HUVEC was restricted to the indicated 
adhesion pathways by the inclusion of the following combinations 
of mAbs: VCAM-I and ELAM-I mAbs to isolate the LFA-I path- 
way; ICAM-1, VCAM-1, and ELAM-1 mAbs to isolate the LFA- 
I/"ICAM-X" pathway; LFA-1 and ELAM-I mAbs to isolate the 
VLA-4/VCAM-I  pathway; LFA-1  and VCAM-1 mAbs to isolate the 
ELAM-I  pathway, and  a  combination  of LFA-1, VLA-4,  and 
ELAM-1 mAbs to maximally inhibit binding (background). Data 
are expressed as mean percent of  cells binding from duplicate wells. 
and data not shown), both were ineffective  in blocking bind- 
ing to resting HUVEC, suggesting that LFA-l-mediated ad- 
hesion to resting HUVEC is mediated by LFA-1 binding to 
another  ligand  ("ICAM-X").  IL-l-activation of  HUVEC, 
which augments ICAM-1 expression (Fig.  3), results in in- 
creased utilization of the LFA-1/ICAM-1 pathway,  since an 
ICAM-1 mAb can now significantly block binding (B vs.  C, 
Fig.  5). 
Acute T Cell Activation Increases LFA-1- and VCAM-1- 
But Not ELAM-l-dependent Adhesion 
To determine which pathways mediate the increased binding 
of activated T cells to HUVEC, binding of resting and PMA- 
activated T ceils to activated HUVEC was restricted to in- 
dividual adhesion pathways by adding the appropriate mAb 
combinations to block each of the other pathways.  Assess- 
ment of resting T cell adhesion to activated HUVEC shows 
that while each pathway plays some role, the strongest bind- 
ing is seen via the ELAM-1 pathway (Fig.  6). Acute activa- 
tion of T cells with PMA results in increased adhesion via 
both LFA-1 and VCAM-1, although LFA-1 is dearly the dom- 
inant adhesion pathway used by PMA-activated T cells.  Fur- 
thermore,  PMA activation  increases  T/HUVEC  adhesion 
measured  in  the  presence  of an  ICAM-I  mAb  added  to 
VCAM-1 and ELAM-1 mAbs, suggesting that adhesion via 
LFA-1 binding to "ICAM-X" is also activation-dependent. In 
contrast, PMA activation does not result in increased adhe- 
sion via ELAM-1. The activation-dependent increase in T 
cell adhesion to HUVEC via the LFA-1 and VLA-4 integrins 
occurs without a change in the level  of cell surface expres- 
sion of LFA-1 and VLA-4 (data not shown) (I1,  45). 
Differential Binding of Naive and Memory CD4 + 
T Cells to HUVEC 
Differential expression of isoforms of the leukocyte surface 
molecule CD45 defines two reciprocal subsets of CIM+ T 
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resting  and IL-l-induced HUVEC. Naive (CD4+CD45RA+) and 
memory (CD4+CD45RO+) T cells were isolated from a represen- 
tative  donor and  assessed  for binding  to  resting  and  activated 
HUVEC; purity of subsets was >95 % as determined by flow cyto- 
metric analysis.  Binding of resting naive (solid bars) and memory 
(open bars) CD4+ T cells and PMA-activated  naive (shaded bars) 
and memory (hatched  bars) cells is shown. Results of two indepen- 
dent  experiments  using  naive  and  memory  cells  isolated  from 
different  donors are presented. 
cells (37,  38, 44).  The subset expressing the CD45RA iso- 
form consists of resting peripheral T cells that have not been 
previously  activated  ("naive" cells).  The reciprocal  subset 
expresses the CD45R0 isoform and represent cells that have 
been previously activated, typically by exposure to antigen, 
and have reverted back to a resting state  ("memory" cells). 
Analysis of these subsets  has shown that in addition to dif- 
ferential expression of CD45 isoforms, there is increased ex- 
pression of  a number of  adhesion molecules, including LFA-1 
and VLA-4, on memory T cells (44, 45). Fig. 7 shows that 
the greater expression of adhesion molecules on memory T 
cells  is  relevant  to  T/HUVEC  interactions.  First,  resting 
purified memory CD4+ T cells bind greater than do resting 
purified naive CD4+ T cells to either resting or IL-l-induced 
Figure 9.  Activation-dependent  binding  of CD4+  T  ceils  to  a 
VCAM-1 L cell transfectant.  Adhesion of resting  (solid bars) and 
PMA-activated  (shaded bars) CD4+ T cells to an untransfected  L 
cell  control and the VCAM-I+ L cell transfectant  LVE3 was as- 
sessed as described in Materials  and Methods.  Data are expressed 
as the mean percent of cells binding from triplicate  wells. 
HUVEC. Second, acute activation of  purified naive and mem- 
ory T cells with PMA results in increased adhesion of both 
subsets  to  HUVEC,  although  PMA-activated  memory  T 
cells still show greater adhesion to HUVEC than do PMA- 
activated naive T  cells. 
Adhesion Pathways Utilized by Naive and Memory 
T Cells in Binding to HUVEC 
mAb blocking studies  were performed to determine  if the 
LFA-1, VCAM-1, and ELAM-1 pathways were equivalently 
used by PMA-activated naive and memory T cells in binding 
to HUVEC. Adhesion of  both PMA-activated naive and mem- 
ory T cells to resting HUVEC is blocked by an LFA-1 mAb 
but not VCAM-1 or ELAM-1 mAbs (compare C, D,  and E 
in Fig. 8). Binding of both subsets via LFA-1 is only partially 
Figure 8.  Differential  utilization  of  the  LFA-1, VCAM-1, and 
ELAM-1 pathways by naive and memory CD4+ T cells in adhesion 
to HUVEC. Binding to resting and IL-l-induced HUVEC of PMA- 
activated  naive (solid bars) and memory (shaded bars) CD4+ T 
cells isolated from a representative  donor in the presence of the in- 
dicated mAbs was assessed as described in Materials  and Methods. 
MAbs were used at the concentrations indicated  in Fig.  4 and 5. 
The LFA-1 mAb was the LFA-1 c~ chain-specific  mAb MHM24 and 
the ICAM-1 mAb used was W-CAM-1. 
Table L Specificity of CD4 ÷ T Cell Adhesion to 
VCAM-1 L  Cell Transfectant LVE3 
mAb added  Specificity  % Inhibition of binding 
None  -  0 
2G7  VCAM-1  75 
MAB  13  VLA ~  chain  100 
L25  VLA-4 t~ chain  100 
MAB  16  VLA-5 ot chain  10 
MHM24  LFA- 1  13 
W-CAM-1  ICAM-1  1 
7A9  ELAM- 1  19 
Binding of PMA-activated CIM +  T cells to the VCAM-1 +  L cell transfeetant 
LVE3 was performed as described  in Materials and Methods. Adhesion was 
measured in the continuous presence of the indicated mAbs used at a saturating 
concentration of 15 #g/ml.  Background binding of PMA-activated CD4+  T 
cell adhesion to an untransfected L cell control was subtracted from the specific 
binding; the indicated percent inhibition of binding in the presence of the indi- 
cated mAb was calculated relative to binding in the absence of any mAb (top 
line). 
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to a VCAM-I transfectant. Binding to the VCAM-1 L cell transfec- 
tant LVE3 of three populations of T cells isolated from the same 
donor was assessed: CD4+, CIM+ naive (CD4-I-CD45RA  +), and 
CIM+  memory (CD4+ CD45RO+). Adhesion of resting (solid 
bars) and PMA-activated (shaded  bars) T cells is shown. Binding 
of all CD4+ cells to an untransfected L cell control was <10% and 
has not been subtracted from the values shown. Data are expressed 
as the mean percent of cells binding from triplicate wells. 
blocked by an ICAM-1 mAb, suggesting that PMA-activated 
naive and memory T cells both use an additional LFA-1 li- 
gand other than ICAM-1  to bind to resting HUVEC (H, I, 
and J  in Fig. 8). Binding of PMA-activated naive T cells to 
activated HUVEC is also substantially inhibited by an LFA-1 
mAb; there is little evidence for a contribution by VCAM-1 
and ELAM-1 in naive T  cell binding to activated HUVEC 
since neither VCAM-1 or ELAM-1 mAbs alone inhibit adhe- 
sion (D and E in Fig. 8) and the combination of either with 
an LFA-1 mAb fails to show significandy greater inhibition 
than the LFA-1 mAb alone (F and G in Fig. 8). In addition, 
an ICAM-1  mAb is almost as effective as an LFA-1 mAb in 
blocking PMA-activated naive T  cell adhesion to activated 
HUVEC, suggesting that LFA-1/ICAM-1 is the predominant 
pathway used by PMA-activated naive T cells to interact with 
activated HUVEC (I vs. J  in Fig.  8). 
In contrast, these studies suggest the utilization of multiple 
additional adhesion pathways by PMA-activated memory T 
cells, while an LFA-I mAb alone partially inhibits memory 
cell adhesion to IL-l-induced HUVEC, the addition of either 
a VCAM-1 or an ELAM-1 mAb results in greater inhibition 
of binding (F and G vs. C in Fig. 8). In addition, the combi- 
nation of an LFA-1, VCAM-1,  and an ELAM-1 mAb max- 
imally inhibits adhesion (Iin Fig. 8), indicating that all three 
molecules are involved in binding of  PMA-activated memory 
T cells to activated HUVEC. Furthermore, in contrast to the 
results obtained with naive T cells, LFA-l-mediated binding 
of PMA-activated memory T cells is only partially inhibited 
by an ICAM-1  mAb (I vs. J  in Fig. 8), suggesting that acti- 
vated memory T cells bind to both ICAM-1  and qCAM-X" 
on activated HUVEC. 
Activation-dependent Binding of CD4 +  T Cells 
to a VCAM-1 L Cell Transfectant 
Our analysis of T/HUVEC adhesion suggests that VLA-4- 
mediated binding to VCAM-1, like VLA-4 binding to its ex- 
tracellular matrix ligand fibronectin, is increased by acute 
activation of the T  cell (Fig. 6). To confirm this finding in 
a simpler system not involving multiple inhibitory mAbs, we 
have analyzed the adhesion of resting and PMA-activated 
CD4+ T cells to mouse L cells transfected with a VCAM-1 
eDNA  clone.  Fig.  9  shows  that  both  resting  and  PMA- 
activated CD4+ T cells bind minimally to an untransfected 
L cell control. While resting T cells also bind minimally to 
the VCAM-1 transfectant, adhesion of PMA-activated T cells 
can be clearly observed (Fig.  9).  This binding is specific, 
since it can be blocked by mAbs specific for VCAM-1,  the 
VLA-4 ct chain, and the common VLA/~ chain but not by 
other relevant mAbs specific for LFA-1, VLA-5, ELAM-1, 
and ICAM-1  (Table I). 
Generation of  functional VCAM-1 transfectants  also enabled 
us to assess  the utilization by purified naive and memory 
CD4+ T cells of the VLA-4/VCAM-1 pathway in isolation. 
The results shown in Fig. 10 confirm the results obtained by 
antibody blocking in our T/HUVEC adhesion assay (Fig. 8). 
While memory T cell adhesion to the VCAM-1 transfectant 
is dramatically increased by PMA-activation, PMA-activa- 
tion of naive CD4+  T  cells results in a minimal change in 
binding.  These results provide further evidence suggesting 
that memory cells utilize the VLA-4/VCAM-I adhesion path- 
way after acute activation with PMA to a much greater extent 
than naive CD4+  T  cells. 
Discussion 
The interaction of T  lymphocytes with endothelial cells is 
critical not only to the normal migration of lymphocytes but 
also to the mobilization and influx of lymphocytes into sites 
of inflammation and tissue injury. The results presented here 
confirm and  extend previous independent studies  demon- 
strating that T  cell interactions with cultured HUVEC are 
mediated by multiple adhesion pathways (10, 15, 36, 39, 43). 
Furthermore, our results demonstrate changes in the domi- 
nance or hierarchy of the various multiple pathways mediat- 
ing T/HUVEC adhesion that depend on the activation state 
of the T cell and the HUVEC, and the differentiation state 
of the T cell. The following discussion will focus on: (a) the 
multitude of adhesion pathways that mediate T/HUVEC in- 
teraction;  (b)  the modes of regulation that play a  role in 
modulating T/HUVEC interaction; (c) the significance of  the 
differential binding of T cell subsets to HUVEC; and (d) the 
relevance of  these findings to lymphocyte  migration and func- 
tion in vivo. 
The hierarchy of the four adhesion pathways that mediate 
T/HUVEC adhesion under the different activation condi- 
tions analyzed in this study are summarized in Table II. We 
highlight the following conclusions from our data. First, we 
have shown that the adhesion of resting CIM+ T cells to IL- 
l-induced HUVEC is mediated by independent pathways of 
adhesion involving LFA-1, VCAM-I, and a newly described 
pathway ofT cell adhesion mediated by ELAM-1 (15, 43, and 
Fig. 6). Multiple pathways working together may be particu- 
larly important for resting T cells, since this would provide 
the best opportunity for a broad spectrum of T  cells to be 
recruited into an inflammatory site. While a role for all four 
pathways can be demonstrated for resting T  cells, it is in- 
teresting to note that the ELAM-1 pathway is as effective as 
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Adhesion via individual pathways 
Overall 
T cell  HUVEC  adhesion  LFA-I/ICAM-1  LFA-  1/"ICAM-X"  VLA-4/VCAM-  1  ?/ELAM-1  Figures 
CD4+ 
Resting  Resting  + 
Activated  Resting  + +  +  + +  -  - 
Resting  Activated  +  5-  +  +  + 
Activated  Activated  + + +  + + +  + + +  + +  + 
CD4+ naive 
Resting  Resting  5- 
Activated  Resting  + +  5-  +  -  - 
Resting  Activated  + 
Activated  Activated  + +  + +  +  -  - 
CD4+ memory 
Resting  Resting  + 
Activated  Resting  + +  5-  + +  -  - 
Resting  Activated  + + 
Activated  Activated  + + +  + + +  + + +  + +  + 
2 
2, 4, 5, and 6 
2and6 
2, 4, 5, and 6 
7 
7and8 
7 
7and 8 
7 
7 and8 
7and8 
7 and 8 
Overall adhesion of the indicated combinations of T cells and HUVEC tested in Figs. 2 and 7 is indicated under the column on a relative scale ranging from low 
(+) to high (+ + + ) levels of adhesion. Contribution  to adhesion via individual pathways  under the different activation conditions studied is indicated on a relative 
scale ranging from no contribution (+) to very strong contribution (+ + +). 
the  other  three  pathways  in  mediating  adhesion  (Fig.  6). 
Thus,  this  recently described pathway of T/HUVEC adhe- 
sion via ELAM-1 may play a particularly critical role in the 
initial attachment of resting T cells to activated endothelium. 
Second, acute activation of the T  cells with PMA results 
in dramatically increased T/HUVEC adhesion (Fig.  2).  In 
contrast to resting T  cells,  where multiple  weak pathways 
cooperate to mediate binding,  PMA-activated T  cell adhe- 
sion to HUVEC is mediated predominantly via the LFA-1 
integrin (Table II). Our results suggest that LFA-1 mediates 
T/HUVEC adhesion by binding not only to its well charac- 
terized ligand,  ICAM-1, but also by binding to another li- 
gand,  "ICAM-X: Even though the ICAM-1 mAbs used in 
our  studies  potently  inhibit  LFA-l-mediated  adhesion  to 
ICAM-1 (4, 42, 55), these mAbs are not as effective as LFA-1 
mAbs in inhibiting T/HUVEC adhesion (Fig. 5); our results 
are  consistent  with  earlier  studies  of T  cell  adhesion  to 
HUVEC suggesting the involvement of an additional LFA-1 
ligand  (10).  The  LFA-1/"ICAM-X" pathway  is  particularly 
dominant in activated T cell binding to resting HUVEC (Fig. 
5).  This  additional  LFA-1  ligand  is  likely  to be ICAM-2, 
which has been reported to be constitutively expressed on 
resting HUVEC and, in contrast to ICAM-1, is not increased 
in expression after IL-1 activation (50). Activation of  HUVEC 
results in increased ICAM-1 expression (Fig. 3) and increased 
LFA-l-dependent adhesion via its more weU-characterized li- 
gand,  ICAM-1  (Fig.  5).  The  functional  significance  of a 
switch in LFA-l-mediated T/HUVEC adhesion from ICAM-1 
to "ICAM-X" or vice versa remains to be defined. 
Third, VLA-4 also plays a role in mediating adhesion of 
T cells to activated HUVEC by binding its ligand VCAM-1. 
The existence of LFA-l-independent pathways was first sug- 
gested by the inability of LFA-1 mAbs to completely inhibit 
T/HUVEC binding  (10).  Furthermore,  despite  the lack of 
LFA-1 expression on ceils of patients with leukocyte adhe- 
sion deficiency (LAD) (1), LAD lymphocytes appear to mi- 
grate normally in vivo and are still able to bind to HUVEC 
in vitro (1,  39).  Recent studies have clearly shown that the 
VLA-4/VCAM-1 pathway can mediate the adhesion of nor- 
mal and LAD lymphocytes to HUVEC (6, 12, 36). Although 
a role for the VLA-4/VCAM-1 pathway can be demonstrated 
in T/HUVEC adhesion,  particularly when both the T  cell 
and HUVEC are activated (Fig. 4), it clearly does not con- 
tribute as strongly to the overall adhesion as does the LFA-1 
pathway. 
The inability of the combination of LFA-1, VCAM-1, and 
ELAM-1  mAbs  to  completely  inhibit  T  cell  adhesion  to 
HUVEC under certain conditions (Fig. 4) suggests the po- 
tential  involvement  of other  receptor/ligand  interactions. 
However, we did not observe any inhibition by mAbs (either 
alone or together with the maximally inhibitory combination 
of LFA-1, VCAM-1 and ELAM-1 mAbs) specific for three ad- 
hesion molecules that might be expected to play a role in T/ 
HUVEC adhesion (data not shown):  (a) LECCAM-1 (also 
MEL-14 in the mouse, Leu-8 in the human) (5),  which has 
been shown in the mouse to mediate the adhesion of lympho- 
cytes to peripheral lymph node high endothelial venules (14, 
47); (b) CD44, which has been implicated in the binding of 
activated  T  ceils  to  IL-l-activated  HUVEC  (31);  and  (c) 
CD2,  which mediates  T  cell  adhesion to many other cell 
types by binding its ligand, LFA-3 (27, 41).  Thus, while we 
do not exclude the potential involvement of other receptor/ 
ligand interactions, our results suggest that LFA-1, VCAM-1 
and ELAM-1 are the major mediators of T  cell adhesion to 
HUVEC. 
Although activation of either the T cell or the endothelial 
cell results in increased T/HUVEC adhesion, the mechanisms 
by which activation increases adhesion are clearly distinct. 
On the endothelial cell, activation by inflammatory cytokines 
results in the increased expression of ICAM-1 and induction 
of expression of VCAM-1 and ELAM-1 (Fig. 3). Thus, endo- 
thelial cells regulate lymphocyte adhesion by changes in the 
level of expression of adhesion molecules as a result of cyto- 
kine  activation.  While  acute activation  of the  T  cell  with 
PMA also results in increased adhesion via LFA-1 and VLA- 
4/VCAM-1  (Fig. 6 and Table II), it is due not to increased 
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in  the  functional activity of these  two  integrins.  Several 
groups have shown that integrin-mediated adhesion of T cells 
to purified ligands such as ICAM-1 and fibronectin and to 
other cells is dependent on the activation state of the T cell 
(11, 44, 45, 54).  While integrin molecules on resting T cells 
are minimally active in binding, integrin-mediated adhesion 
can be dramatically upregulated within minutes by acute ac- 
tivation of the T cell without a change in the quantitative level 
of integrin cell surface expression. The exact mechanism by 
which activation regulates integrin function currently re- 
mains undefined. Our results show that T cell adhesion to 
HUVEC via the LFA-1 and VLA-4 integrins, like adhesion 
to purified ligands, is similarly regulated by the activation 
state of the T cell. Furthermore, our data suggest that LFA-1- 
mediated adhesion to its alternative ligand "ICAM-X" is also 
regulated by T cell activation (Fig. 5). 
VLA-4 has both an extracellular matrix ligand, fibronectin 
(13, 16, 45, 56), and a cell surface ligand, VCAM-1 (12). Our 
results demonstrate for the first time that VLA-4-mediated 
adhesion to VCAM-1 is upregulated by acute activation of  the 
T cell (Figs.  6 and 9).  Thus, although the binding sites for 
VCAM-1 and fibronectin on VLA-4 do not appear to be iden- 
tical (12), a common mode of regulation exists for VLA-4- 
mediated adhesion to both ligands. 
In contrast to the LFA-1 and VLA-4/VCAM-1  pathways, 
the ELAM-1 pathway is neither increased or decreased by 
acute T cell activation. This has been demonstrated by show- 
ing that both resting and PMA-activated CD4+ T cells bind 
comparably  to IL-l-induced  HUVEC when  the ELAM-1 path- 
way is isolated by adding mAbs that block the other pathway 
(Fig. 6). Furthermore, we have recently shown using purified 
ELAM-1  that CD4+  T cells, whether resting or activated, 
specifically adhere to ELAM-1 and this binding is not aug- 
mented by PMA activation (43). 
The differential expression of an ensemble of adhesion 
molecules, including LFA-1 and VLA-4, on naive and mem- 
ory CD4+ T cells is associated with differential adhesion of 
these T cell subsets to purified ligands (44, 45) and to other 
cells (7, 9, 34). While both naive and memory T cells express 
LFA-1 and VLA-4, there is about a twofold greater expression 
of  LFA-1 and a three- to fourfold  greater expression of  VLA-4 
on memory CD4+  T cells (44).  Our results show that for 
any particular activation state of the T cell or the HUVEC, 
memory T cells bind more strongly to HUVEC than compa- 
rable naive T cells isolated from the same donor (Fig. 7). 
The greater adhesion of memory T cells to HUVEC is due 
to increased utilization of all four pathways mediating T/ 
HUVEC adhesion; adhesion of PMA-activated naive T cells 
is  mediated predominantly via the  LFA-1 pathways.  Our 
studies with both HUVEC and VCAM-1 transfectants do not 
show  significant VLA-4-mediated adhesion of PMA-acti- 
vated naive T ceils to VCAM-1 (Figs. 8 and 10). This result 
is surprising,  since naive T cells express significant levels 
of VLA-4 (45).  Clearly overall integrin function is not im- 
paired on naive T cells, since significant binding of PMA- 
activated naive T cells to activated HUVEC occurs via the 
related integrin LFA-1. This suggests  that on naive T cells, 
VLA-4, in contrast to LFA-1, functions quite poorly in medi- 
ating adhesion to HUVEC. Consistent with our studies using 
purified ELAM-1 (43), we also find no evidence for naive 
T cell adhesion to HUVEC via ELAM-1 (Fig. 8). The data 
in Fig. 7 also show a dramatic increase in adhesion of resting 
memory T cells after HUVEC activation. Since LFA-1 and 
VLA-4 function on resting T cells is minimal (Table II), this 
suggests that the ELAM-1 pathway may be particularly criti- 
cal in mediating adhesion of resting memory T cells to acti- 
vated HUVEC (43). 
The  delineation of the  various  adhesion molecules in- 
volved in T/HUVEC interaction and the ways in which their 
function is regulated is important for understanding how T 
cell interactions with endothelium in vivo regulate normal 
lymphocyte trafficking and influx into sites of inflammation 
(32,  51). It has been previously shown that memory T cells 
are preferentially found in tissue and in sites of inflammation 
(21-23,  34).  The increased utilization of multiple adhesion 
pathways by memory T cells in T/HUVEC binding suggests 
that compared to naive T cells, memory T cells have multiple 
mechanisms by which to attach and migrate into tissue. Our 
results may also be relevant to an understanding of normal 
lymphocyte trafficking, since  studies by Mackay and co- 
workers have demonstrated differential trafficking patterns 
of naive and memory T cells in vivo (25). The utilization of 
multiple adhesion pathways by memory but not naive cells 
in HUVEC binding may be critical to such differential recir- 
culation of these subsets in vivo.  The dramatic effects of T 
cell activation on the strength of T/HUVEC adhesion further 
suggests that the small percentage of acutely activated T cells 
found in the peripheral blood may be particularly likely to 
migrate into tissue and inflammatory sites. 
Why are so many adhesion pathways involved in mediating 
T/HUVEC adhesion? The overall complexity likely reflects 
the critical importance of this adhesive interaction to overall 
lymphocyte function. A complex adhesion system has sev- 
eral important advantages. First, the existence of multiple 
adhesion pathways provides an important safeguard of re- 
dundancy within the system. Such redundancy in adhesion 
is seen in other critically important cell-cell interactions, 
such as interactions of cytotoxic T lymphocytes with target 
cells (40).  Second, multiple adhesion pathways allow for in- 
creased adhesion through cooperativity. This is particularly 
evident in adhesion of PMA-activated memory T cells to IL- 
l-induced HUVEC, where four adhesion pathways (LFA-1/ 
ICAM-1, LFA-1/"ICAM-X" VLA-4/VCAM-1,  and ELAM-1) 
contribute to mediate binding.  Nevertheless,  studies with 
transfectants and purified ligand show that VCAM-1 and 
ELAM-1  are sufficient on their own to mediate adhesion 
(Fig. 9) (43).  Third, different adhesion pathways can be dif- 
ferentially regulated.  For  example,  while the  LFA-1 and 
VCAM-1 pathways are rapidly upregulated after T cell acti- 
vation, the ELAM-1 pathway is unaffected by the activation 
state of the T cell. Furthermore, memory but not naive T 
ceils preferentially utilize both the ELAM-I and VLA-4 ad- 
hesion pathways. The nature of  the activation signal delivered 
to HUVEC may also play a role in differential utilization of 
these pathways,  since in vitro studies show that some cyto- 
kines,  such as IL-4,  specifically induce VCAM-1 but not 
ELAM-1 expression (29).  Thus, multiple mechanisms may 
serve to independently regulate these various adhesion path- 
ways at specific inflammatory sites in vivo. Finally, the exis- 
tence of multiple adhesion pathways in T/HUVEC interac- 
tion may reflect the need for certain molecules to carry out 
distinct functions that are not mediated by other molecules: 
some of  the pathways may also transduce intercellular signals 
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others may be critical  to transendothelial  migration. 
In  summary,  we  have  shown that  the hierarchy  of the 
four pathways  (LFA-I/ICAM-1,  LFA-1/"ICAM-X;  VLA-4/ 
VCAM-1, and ELAM-1) mediating T/HUVEC adhesion varies 
with the activation state of the interacting cells and the differ- 
entiation state of the T cell. These results are critical not only 
to our understanding of lymphocyte migration but also pro- 
vide important insights into how functionally important cell- 
cell interactions  are regulated  by multiple adhesion mole- 
cules. 
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Note Added in Proof.  A more detailed description of the LVE-3 cell line 
can be obtained from Polle,  T., W.  Newman, G.  Raghunathan, and T. 
Venkat Gopal.  1991.  Structural and functional studies of full-length vascu- 
lar cell adhesion molecule-1  (VCAM-I). Internal duplication and homology 
to several adhesion proteins. DNA  Cell Biol.  In press. 
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